Clinical trial
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
NCT00001572 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001572 |
|---|---|
| Title | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype |
| Official title | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B Cell Lymphoma, Follicular Lymphoma, Neoplasm |
| Intervention type | Drug |
| Interventions | Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug |
| Enrollment | 21 |
| Start date | Jan 30, 1997 |
| Primary completion | Jul 31, 1999 |
| Completion | Nov 2, 2010 |
| First posted | Nov 4, 1999 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: